Phase 2b DME Trial Completes Enrollment

 

A phase 2b trial assessing the safety and efficacy of ALG-1001 (Luminate, Allegro) as DME therapy has completed enrollment. The company expects to report top-line data by the third quarter of 2016.

DEL MAR is a double-masked, placebo-controlled, multicenter 6-month phase 2b trial evaluating the safety and efficacy of intravitreal ALG-1001 compared with bevacizumab (Avastin, Genentech) in patients with DME. In the trial, 120 patients will be randomly assigned to receive one of three doses of ALG-1001 (1.0 mg, 2.0 mg, or 3.0 mg) or bevacizumab.

 

Contact Info

Bryn Mawr Communications LLC
1008 Upper Gulph Road, Suite 200
Wayne, PA 19087

Phone: 484-581-1800
Fax: 484-581-1818

Karen Roman
Editor-in-Chief
484-581-1827
kroman@bmctoday.com

Janet Burk
Publisher
214-394-3551
jburk@bmctoday.com

About Retina Today

Retina Today is a publication that delivers the latest research and clinical developments from areas such as medical retina, retinal surgery, vitreous, diabetes, retinal imaging, posterior segment oncology and ocular trauma. Each issue provides insight from well-respected specialists on cutting-edge therapies and surgical techniques that are currently in use and on the horizon.